5.09
price down icon4.32%   -0.23
after-market After Hours: 5.09
loading
Aldeyra Therapeutics Inc stock is traded at $5.09, with a volume of 1.21M. It is down -4.32% in the last 24 hours and up +34.30% over the past month. Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
See More
Previous Close:
$5.32
Open:
$5.3
24h Volume:
1.21M
Relative Volume:
1.08
Market Cap:
$304.87M
Revenue:
-
Net Income/Loss:
$-44.80M
P/E Ratio:
-6.7867
EPS:
-0.75
Net Cash Flow:
$-30.67M
1W Performance:
-5.04%
1M Performance:
+34.30%
6M Performance:
-1.74%
1Y Performance:
+29.19%
1-Day Range:
Value
$5.02
$5.32
1-Week Range:
Value
$5.02
$5.62
52-Week Range:
Value
$1.14
$7.20

Aldeyra Therapeutics Inc Stock (ALDX) Company Profile

Name
Name
Aldeyra Therapeutics Inc
Name
Phone
781-761-4904
Name
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Name
Employee
8
Name
Twitter
@aldeyraaldx
Name
Next Earnings Date
2024-11-18
Name
Latest SEC Filings
Name
ALDX's Discussions on Twitter

Compare ALDX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ALDX
Aldeyra Therapeutics Inc
5.09 318.64M 0 -44.80M -30.67M -0.75
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
468.41 118.34B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.14 60.31B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
330.55 42.35B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
598.79 36.43B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
305.74 31.87B 3.81B -644.79M -669.77M -6.24

Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-03-24 Upgrade Oppenheimer Perform → Outperform
Apr-02-24 Resumed H.C. Wainwright Buy
Apr-27-22 Resumed H.C. Wainwright Buy
Feb-08-21 Initiated H.C. Wainwright Buy
Dec-16-20 Initiated Berenberg Buy
Oct-30-20 Initiated Jefferies Buy
Oct-16-20 Initiated BTIG Research Buy
Sep-22-20 Initiated Alliance Global Partners Buy
May-12-20 Initiated Oppenheimer Outperform
Dec-04-18 Initiated Citigroup Buy
Sep-26-18 Reiterated Cantor Fitzgerald Overweight
Sep-13-18 Initiated Janney Buy
Jan-26-18 Initiated Seaport Global Securities Buy
Sep-26-16 Initiated H.C. Wainwright Buy
Jul-01-16 Initiated Stifel Buy
Jul-01-15 Initiated Canaccord Genuity Buy
Mar-25-15 Initiated Chardan Capital Markets Buy
Mar-20-15 Reiterated H.C. Wainwright Buy
Nov-18-14 Initiated H.C. Wainwright Buy
Jun-19-14 Initiated Aegis Capital Buy
View All

Aldeyra Therapeutics Inc Stock (ALDX) Latest News

pulisher
Jul 29, 2025

Why did ALDX's EPS remain stagnant in recent quarters? - AInvest

Jul 29, 2025
pulisher
Jul 28, 2025

How does Aldeyra Therapeutics Inc. generate profit in a changing economyMarket Forecast Target Finder For 2025 - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How Aldeyra Therapeutics Inc. stock performs during market volatilityFundamental Growth Stock Analysis Shows Strength - metal.it

Jul 28, 2025
pulisher
Jul 27, 2025

What makes Aldeyra Therapeutics Inc. stock attractive to long term investorsAnalyst Grade Signals - metal.it

Jul 27, 2025
pulisher
Jul 27, 2025

What is the risk reward ratio of investing in Aldeyra Therapeutics Inc. stockCapitalize on strategic market trends - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Why is Aldeyra Therapeutics Inc. stock attracting strong analyst attentionDiscover stocks with explosive upside potential - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What are Aldeyra Therapeutics Inc. company’s key revenue driversUnlock high-yield investment opportunities - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

How volatile is Aldeyra Therapeutics Inc. stock compared to the marketInvest smarter with expert stock recommendations - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 26, 2025

Aldeyra Therapeutics receives orphan designation for ADX-2191 from EMA - Ophthalmology Times

Jul 26, 2025
pulisher
Jul 25, 2025

Is Aldeyra Therapeutics Inc. a good long term investmentExplosive earning power - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

Aldeyra Therapeutics Receives Orphan Designation from the Europe - GuruFocus

Jul 24, 2025
pulisher
Jul 24, 2025

What drives Aldeyra Therapeutics Inc. stock priceFree Risk Assessment Services - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

What analysts say about Aldeyra Therapeutics Inc. stockExceptional gains - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

EMA grants orphan designation to ADX-2191 (Aldeyra Therapeutics) for inherited retinal dystrophies - Ophthalmology Times Europe

Jul 24, 2025
pulisher
Jul 24, 2025

EMA grants orphan designation for Aldeyra’s eye treatment By Investing.com - Investing.com India

Jul 24, 2025
pulisher
Jul 24, 2025

EMA grants orphan designation for Aldeyra’s eye treatment - Investing.com

Jul 24, 2025
pulisher
Jul 24, 2025

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa - The Globe and Mail

Jul 24, 2025
pulisher
Jul 22, 2025

Published on: 2025-07-23 18:29:07 - Autocar Professional

Jul 22, 2025
pulisher
Jul 22, 2025

Aldeyra Therapeutics Inc. Stock Analysis and ForecastSuperior returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 19, 2025

ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap - MSN

Jul 19, 2025
pulisher
Jul 18, 2025

FDA accepts Aldeyra's resubmitted reproxalap NDA - Eyes On Eyecare

Jul 18, 2025
pulisher
Jul 17, 2025

FDA accepts for review Aldeyra Therapeutics’ resubmitted new drug application for reproxalap - Optometry Times

Jul 17, 2025
pulisher
Jul 17, 2025

Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics - The Globe and Mail

Jul 17, 2025
pulisher
Jul 17, 2025

Aldeyra Therapeutics Announces FDA Acceptance for Review of Repr - GuruFocus

Jul 17, 2025
pulisher
Jul 17, 2025

Aldeyra says dry eye therapy undergoes FDA review (ALDX:NASDAQ) - Seeking Alpha

Jul 17, 2025
pulisher
Jul 17, 2025

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease - Lelezard

Jul 17, 2025
pulisher
Jul 17, 2025

FDA Accepts Aldeyra’s Reproxalap Application for Review - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

FDA Reviews Aldeyra's (ALDX) Reproxalap for Dry Eye Disease | AL - GuruFocus

Jul 17, 2025
pulisher
Jul 17, 2025

FDA accepts Aldeyra’s resubmitted NDA for dry eye disease drug By Investing.com - Investing.com Nigeria

Jul 17, 2025
pulisher
Jul 17, 2025

FDA accepts Aldeyra’s resubmitted NDA for dry eye disease drug - Investing.com

Jul 17, 2025
pulisher
Jul 17, 2025

FDA Reviews Breakthrough Dry Eye Drug: Aldeyra's Reproxalap Could Transform Treatment Landscape - Stock Titan

Jul 17, 2025
pulisher
Jul 16, 2025

Aldeyra Therapeutics (ALDX) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN

Jul 16, 2025
pulisher
Jul 16, 2025

why aldeyra therapeutics inc. stock attracts strong analyst attentionFree Exclusive Investment Tips - Newser

Jul 16, 2025
pulisher
Jul 16, 2025

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats - The Globe and Mail

Jul 16, 2025
pulisher
Jul 15, 2025

Why Aldeyra Therapeutics Inc. stock attracts strong analyst attentionTriple Digit Return Forecasts - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Aldeyra Therapeutics Inc. stock price move sharplyCapital Safe Smart Trades - Newser

Jul 15, 2025

Aldeyra Therapeutics Inc Stock (ALDX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$77.38
price up icon 10.28%
$37.27
price up icon 0.57%
$105.00
price up icon 3.19%
$26.74
price down icon 2.59%
$111.48
price down icon 1.16%
biotechnology ONC
$305.74
price up icon 3.81%
Cap:     |  Volume (24h):